North America Exosome Therapeutic Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Dec 2019
  • North America
  • 350 Pages
  • No of Tables: 96
  • No of Figures: 53

North America Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), By Country (U.S., Mexico), Market Trends and Forecast to 2026

Market Analysis and Insights: North America Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing at a CAGR of 22.2% in the forecast period of 2019 to 2026 and expected to reach USD 16,979.73 million by 2026 from USD 3,398.20 million in 2018. Increasing prevalence of Lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases and increasing demand for anti-aging therapies are the factors for the market growth.

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Rising research activities on exosomes for the treatment of various diseases such as skin, cancer and others to enhance the market growth. For instance, In August, Evox Therapeutics has received patents grant by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) for three key patents which includes exosome-mediated RNA therapeutics and targeted exosome drug delivery. The patent grant will help company to increase revenue generation in the future.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Exosome Therapeutic Market Scope and Market Size

North America exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes less harmful compare than hybrid exosomes as well as rising cases of chronic disease increase demand of better alternative treatment. For instance In August 2019, Evox Therapeutics has received patents grant by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) for three key patents which includes exosome-mediated RNA therapeutics and targeted exosome drug delivery. The Patent grant will help company to increase revenue generation in the future.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because they are widely used in clinical trial study for various diseases in the U.S as well as Mesenchymal stem cells have gained popularity in the field of regenerative medicines due to their better safety profile in human patients and recently confirmed efficacy in late-stage clinical studies.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy segment is dominating in the market because rising case of cancers in the North America and chemotherapy as a primary treatment to destroy cancer cells, As per the American Cancer Society 63.00% patients treated with chemotherapy in the U.S.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules such as RNA, lipids and proteins. The structure of extracellular vesicles changes in pathological and physiological conditions as well as play important role in repair and regeneration. So it is used rising for therapeutic purpose.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynaecology disorders, organ transplantation and others. Oncology is dominating in the market because rising cases of oncology disease in the North America. As per the American Cancer Society in 2019, around 228,150 news cases of lung cancers raised in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route of administration is dominating in the market due to drug is directly supplied in the blood, better bioavailability and reliable dose.

Based on end user, the market is segmented into hospitals, diagnostic centres and research & academic institutes and others. Hospital is dominating in the market because hospitals provide better treatment facilities and availability of medical staffs. As per the American Hospitals Association, in 2017, around 6200 active hospitals in the U.S

Exosome Therapeutic Market Country Level Analysis

The North America market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration, end user.

The countries covered in the exosome therapeutic market report are U.S., Mexico in North America.

North America exosome therapeutics market is growing due to rising cases of disease such as cancers; skin disease is expected to grow at the significant growth rate in the forecast period of 2190 to 2026 because of rising awareness about the advance treatment alternatives. For instance In the United States, as per the National Cancer Institute report of 2018, an estimated 1.7 million new cases of cancer were diagnosed in the country and nearly 0.6 million patients died due to cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strong Investment in Research and Development Activities and New Technology Penetration

North America exosome therapeutics market also provides you with detailed market analysis for every country growth in availability base of different products for exosomes therapeutics market, impact of technology using line curves and changes in medical regulatory scenarios and their impact on exosomes therapeutics market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Exosome Therapeutics Market Share Analysis

North America exosome therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to North America electric vehicle market.

The major players covered in the report are Stem Cells Group, Aegle Therpeutics, Avalon Globocare Corp, Boehringer Ingelheim International GMBH, Capricor Therapeutics , Codiak Biosciences, Creative Medical Technology Holdings, INC., Jazz Pharmaceuticals, INC., Reneuron Group PLC, United Therapeutics Corporation, among other players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For instance,

  • In January 2019, Jazz Pharmaceuticals, Inc. has collaborated with Codiak BioSciences to develop and commercialize exosome therapeutics to treat cancer. The collaboration will help the company to address issues which have been often implicated in solid tumors and hematological malignancies.
  • In May 2018, Creative Medical Technology Holdings, Inc. has filed patent for AmnioStem stem cells to use it for reducing/reversing natural aging. The patent will help the company to recapitulate effect in technically and an ethical feasible manner and to generate revenue in future as usage of young blood in stimulation of regeneration in aged patients which was gaining attention in the area of regenerative medicine.

Partnership, collaboration and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for electric vehicles through expanded model range

Customization Available : North America Exosome Therapeutic Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EXOSOMES USED AS DRUG/GENE DELIVERY CARRIERS.

TABLE 2 COMPARISON OF CONVENTIONAL AND MICROFLUIDICS-BASEDEXOSOME ISOLATION TECHNIQUES

TABLE 3 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS

TABLE 4 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 5 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 6 NORTH AMERICA HYBRID EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 7 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 8 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 9 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 10 NORTH AMERICA MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTIC MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 11 NORTH AMERICA DENDRITIC CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 12 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 14 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 15 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 16 NORTH AMERICA MILK IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 NORTH AMERICA SALIVA IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 18 NORTH AMERICA URINE IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 20 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 21 NORTH AMERICA CHEMOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 22 NORTH AMERICA IMMUNOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 23 NORTH AMERICA GENE THERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 24 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY,  2017-2026 (USD MILLION)

TABLE 25 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 26 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET,  BY SOURCE, 2017-2026 (USD MILLION)

TABLE 27 NORTH AMERICA SMALL MOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 28 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 29 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 30 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 31 NORTH AMERICA CARDIAC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 32 NORTH AMERICA METABOLIC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 33 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 34 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 35 NORTH AMERICA BLOOD DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 36 NORTH AMERICA GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTIC MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 37 NORTH AMERICA INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 NORTH AMERICA ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 40 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 41 NORTH AMERICA PARENTERAL IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 42 NORTH AMERICA ORAL IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 43 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 44 NORTH AMERICA HOSPITALS IN EXOSOME THERAPEUTIC MARKET, BY REGION,  2017-2026 (USD MILLION)

TABLE 45 NORTH AMERICA RESEARCH & ACADEMIC INSTITUTES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 46 NORTH AMERICA DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTIC MARKET,  BY REGION, 2017-2026 (USD MILLION)

TABLE 47 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY COUNTRY  2017-2026 (USD MILLION)

TABLE 48 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 49 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET,  BY TYPE, 2017-2026 (USD MILLION)

TABLE 50 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 51 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 52 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 53 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY,  2017-2026 (USD MILLION)

TABLE 54 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY,  2017-2026 (USD MILLION)

TABLE 55 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET,  BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 56 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 57 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 58 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 59 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 60 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER,  2017-2026 (USD MILLION)

TABLE 61 U.S. EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 62 U.S. NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 63 U.S. EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 64 U.S. BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 65 U.S. BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 66 U.S. EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 67 U.S. EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY,  2017-2026 (USD MILLION)

TABLE 68 U.S. BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 69 U.S. EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 70 U.S. ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 71 U.S. NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 72 U.S. EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 73 U.S. EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 74 MEXICO EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 75 MEXICO NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE,  2017-2026 (USD MILLION)

TABLE 76 MEXICO EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 77 MEXICO BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 78 MEXICO BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE,  2017-2026 (USD MILLION)

TABLE 79 MEXICO EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 80 MEXICO EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY,  2017-2026 (USD MILLION)

TABLE 81 MEXICO BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 82 MEXICO EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 83 MEXICO ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 84 MEXICO NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION,  2017-2026 (USD MILLION)

TABLE 85 MEXICO EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION,  2017-2026 (USD MILLION)

TABLE 86 MEXICO EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions